Fingerprint
Dive into the research topics of 'Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study
Sara M. Tolaney*, Hovav Nechushtan, Ilan Gil Ron, Patrick Schöffski, Ahmad Awada, Chris A. Yasenchak, A. Douglas Laird, Bridget O’Keeffe, Geoffrey I. Shapiro, Eric P. Winer
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
39
Scopus
citations